Drug
Aumolertinib clinical trials
Also written Almonertinib and HS-10296.
- studies test it
- 48
- open now
- 19
- in phase 3
- 14
- first study started
- 2017
Keep track of what changes. Save the aumolertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
48 studies that test it; most in 2021 (15)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 8 |
| 2021 | 15 |
| 2022 | 7 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 28
- Phase 3
- 14
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 35
Jiangsu Hansoh Pharmaceutical Co., Ltd. (8) · Sun Yat-sen University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Qianfoshan Hospital (2) · The First Affiliated Hospital of Guangzhou Medical University (2)
Often tested with
Tested in the same studies.
Pemetrexed (3) · Ruzaltatug rezetecan (2) · Palbociclib (2) · Carboplatin (2) · Cisplatin (1) · Adebrelimab (1) · C-Met Inhibitor HS-10241 (1) · Anlotinib (1)
Studies
Open first, then newest update. How each study uses aumolertinib is read from its arms, and is right about nine times in ten.
Testing it · 48
- MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNot applicablePeking University People's HospitalNCT07873086Written as Aumolertinib
- An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07863167Written as almonertinib
- A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07130916Written as Aumolertinib
- A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingPhase 2Sichuan UniversityNCT06951464Written as Almonertinib
- A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS MutationsRecruitingPhase 1/2Sun Yat-sen UniversityNCT06947811Written as Almonertinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Almonertinib 110 MG
- Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNot yet recruitingPhase 2Peking Union Medical College HospitalNCT06752408Written as Aumolertinib
- Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06463171Written as Almonertinib
- Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.RecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT05946460Written as Aumolertinib
- A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI TherapyNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06110663Written as HS-10241+ Almonertinib
- Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceRecruitingPhase 3Qianfoshan HospitalNCT06043973Written as almonertinib
- Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung CancerNot yet recruitingPhase 2/3Laibin People's HospitalNCT05994339Written as Almonertinib
- Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade PatternsRecruitingPhase 2Baohui HanNCT04922138Written as Aumolertinib
- Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-MutationNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT05778149Written as Aumolertinib,Anlotinib
- Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic HepatopathyRecruitingPhase 2West China HospitalNCT05662813Written as Almonertinib
- A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung CancerRecruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT04951635Written as Almonertinib
- Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationPhase 3Chinese Academy of Medical SciencesNCT04762459Written as Almonertinib
- Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung CancerNot yet recruitingPhase 2Qianfoshan HospitalNCT04755738Written as Almonertinib plus microwave ablation
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT04455594Written as Almonertinib
- A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCActive, not recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07183189Written as SHR-A2009 ; Aumolertinib
See all 48 studies that test aumolertinib →
Given in every arm · 5 — aumolertinib is usual care beside what is tested
- First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNot yet recruitingPhase 2Yongsheng WangNCT07699952Written as Almonertinib
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3Hansoh BioMedical R&D CompanyNCT06417008Written as Aumolertinib
- Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung CancerRecruitingPhase 3Shanghai Cancer Hospital, ChinaNCT05800223Written as Almonertinib
- Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain MetastasesRecruitingPhase 3Sun Yat-sen UniversityNCT05768490Written as Almonertinib
- Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerStatus unknownPhase 2Fudan UniversityNCT04592666Written as Almonertinib
Codes
What other systems call aumolertinib · ClinicalTrials.gg INT001649
- MeSH (NLM) C000718108aumolertinibOne source NLM
- UNII (FDA) T4RS462G19AUMOLERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q105317437aumolertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C133691AumolertinibOne source FDA
- DrugBank DB16640One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718108 | aumolertinib | One source NLM |
| UNII (FDA) | T4RS462G19 | AUMOLERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105317437 | aumolertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C133691 | Aumolertinib | One source FDA |
| DrugBank | DB16640 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.